Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On January 15, 2023, Catalyst Biosciences, Inc. (the "Company'") terminated
Grant Blouse Ph.D. from his position as the Chief Scientific Officer of the
Company, effective as of January 15, 2023 (the "Effective Date"). In connection
with his termination, Dr. Blouse is entitled to receive the severance payments
that are provided for in his employment agreement with the Company, which have
been previously described in the Company's most recent proxy statement, along
with other bonus payments previously disclosed by the Company in the Current
Report on Form 8-K that was filed on December 27, 2022. Dr. Blouse has agreed to
provide consulting services following the Effective Date to provide advice
regarding the potential sale or license of the Company's legacy hemophilia
programs.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
Number Description
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
CATALYST BIOSCIENCES